Find a Clinical Trial

Trial Description: This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.

• Conditions: large cell neuroendocrine carcinoma of the lung, small cell lung cancer extensive stage
• Phase: I
• Trial ID: NCT05680922
• Protocol ID: 23-158

Trial Description: This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155

• Conditions: anaplastic lymphoma kinase gene translocation, lung cancer, met amplification, nsclc, relapsed cancer, resistant cancer, ros1 rearrangement
• Phase: I/II
• Trial ID: NCT04292119
• Protocol ID: 19-629

Trial Description: Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

• Conditions: alk-positive non small cell lung cancer (nsclc) and ros1-positive nsclc
• Phase: I/II
• Trial ID: NCT01970865
• Protocol ID: 13-408

Trial Description: The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

• Conditions: melanoma, mismatch repair-proficient colorectal cancer, non-small cell lung cancer
• Phase: I/II
• Trial ID: NCT02437136
• Protocol ID: 15-322

Trial Description: This research study is evaluating a behavioral intervention designed to help people with advanced lung cancer manage dyspnea (i.e., breathlessness or shortness-of-breath).

• Conditions: lung cancer
• Phase: Not Applicable
• Trial ID: NCT03089125
• Protocol ID: 16-476

Trial Description: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

• Conditions: stage ib lung non-small cell carcinoma ajcc v7, stage ii lung non-small cell cancer ajcc v7, stage iiia lung non-small cell cancer ajcc v7
• Phase: III
• Trial ID: NCT02595944
• Protocol ID: 16-723

Trial Description: This research study is evaluating the combination of olaparib and temozolomide as a possible treatment for Small Cell Lung Cancer.

• Conditions: small cell lung cancer
• Phase: I/II
• Trial ID: NCT02446704
• Protocol ID: 15-121

Trial Description: This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

• Conditions: stage iia lung cancer ajcc v8, stage iib lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8
• Phase: III
• Trial ID: NCT02194738
• Protocol ID: 15-700

Trial Description: This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.

• Conditions: metastatic non-small cell lung cancer
• Phase: II
• Trial ID: NCT04410796
• Protocol ID: 22-331

Trial Description: This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene. The drugs involved in this study are: - Palbociclib - Binimetinib

• Conditions: lung cancer
• Phase: I
• Trial ID: NCT03170206
• Protocol ID: 16-531

Trial Description: This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: - Nivolumab - Carboplatin - Pemetrexed - Ipilimumab

• Conditions: lung cancer
• Phase: II
• Trial ID: NCT03256136
• Protocol ID: 17-011

Trial Description: This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer and their families.

• Conditions: lung cancer
• Phase: Not Applicable
• Trial ID: NCT03375489
• Protocol ID: 17-484

Trial Description: This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.

• Conditions: lung cancer
• Phase: I
• Trial ID: NCT03891615
• Protocol ID: 18-613

Trial Description: The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise intervention is feasible and improves various health outcomes among individuals with advanced lung cancer receiving immunotherapy. The names of the study interventions involved in this study are: - High-intensity interval training (HIIT) (Home-based, virtually supervised, high intensity training in an interval fashion) - Moderate-intensity continuous training (MICT) (Home-based, virtually supervised, moderate intensity in a continuous fashion) - Usual care (UC)

• Conditions: advanced lung cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT06026111
• Protocol ID: 23-247

Trial Description: The aim of this study is to evaluate the efficacy of a brief psychoeducational intervention to improve quality of life in patients with lung cancer who are transitioning from active treatment to surveillance.

• Conditions: lung cancer
• Phase: Not Applicable
• Trial ID: NCT05087251
• Protocol ID: 21-426

Trial Description: The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

• Conditions: small cell lung cancer
• Phase: I
• Trial ID: NCT03898791
• Protocol ID: 19-246

Trial Description: This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT04484142
• Protocol ID: 20-602

Trial Description: This research study is studying two immunotherapy drugs as a possible treatment for advanced non-small cell lung cancer (NSCLC). The drugs involved in this study are: - Ipilimumab - Nivolumab

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT03425331
• Protocol ID: 17-566

Trial Description: This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

• Conditions: kras activating mutation, non small cell lung cancer
• Phase: II
• Trial ID: NCT04620330
• Protocol ID: 21-174

Trial Description: This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : - Lorlatinib

• Conditions: non-small cell lung cancer (nsclc)
• Phase: II
• Trial ID: NCT02927340
• Protocol ID: 16-248

Trial Description: This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

• Conditions: metastatic non small cell lung cancer
• Phase: II
• Trial ID: NCT04614103
• Protocol ID: 20-647

Trial Description: This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.

• Conditions: coping skills, non small cell lung cancer, quality of life
• Phase: I/II
• Trial ID: NCT04629300
• Protocol ID: 20-398

Trial Description: The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

• Conditions: carcinoma non-small-cell lung
• Phase: III
• Trial ID: NCT04025879
• Protocol ID: 19-507

Trial Description: This research study is studying a drug combination as a possible treatment for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. The drugs involved in this study are: - Alectinib - Cobimetinib

• Conditions: non-small cell lung cancer
• Phase: I/II
• Trial ID: NCT03202940
• Protocol ID: 17-112

Trial Description: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

• Conditions: lung cancer
• Phase: III
• Trial ID: NCT00632853
• Protocol ID: 12-134

. Chemotherapy and radiation is the standard treatment for the patients with stage III non-small cell lung cancer (NSCLC). For people with epidermal growth factor receptor (EGFR) mutations, adding a type of drug called a tyrosine kinase inhibitor (TKI) can help increase the response to treatment. Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more advanced NSCLC. Results from that study indicate it may be helpful in treating NSCLC with EGFR mutations. In this study, patients with stage III NSCLC and EGFR mutations will receive

• Conditions: lung cancer
• Phase: II
• Trial ID: NCT01553942
• Protocol ID: 11-464

Trial Description: This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The drugs involved in this study are: - Osimertinib (Tagrisso) - Selumetinib

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT03392246
• Protocol ID: 17-540

Trial Description: This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The interventions involved in this study are: - Osimertinib (Tagrisso) - Gefitinib (Iressa)

• Conditions: non-small cell lung cancer
• Phase: I
• Trial ID: NCT03122717
• Protocol ID: 16-627

Trial Description: This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: - Osimertinib (Tagrisso)

• Conditions: carcinoma non-small-cell lung
• Phase: II
• Trial ID: NCT03586453
• Protocol ID: 18-070

Trial Description: This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

• Conditions: metastatic non small cell lung cancer
• Phase: III
• Trial ID: NCT05215340
• Protocol ID: 22-296

Trial Description: This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.

• Conditions: non-small cell lung cancer
• Phase: III
• Trial ID: NCT04656652
• Protocol ID: 20-724

Trial Description: This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

• Conditions: alk gene rearrangement, alk gene translocation, alk positive, stage ib non-small cell lung carcinoma ajcc v7, stage ii non-small cell lung cancer ajcc v7, stage iia non-small cell lung carcinoma ajcc v7, stage iib non-small cell lung carcinoma ajcc v7, stage iiia non-small cell lung cancer ajcc v7
• Phase: III
• Trial ID: NCT02201992
• Protocol ID: 15-702

Trial Description: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

• Conditions: advanced malignant solid neoplasm, metastatic lung non-small cell carcinoma, metastatic lung small cell carcinoma, metastatic pancreatic adenocarcinoma, metastatic triple-negative breast carcinoma, pancreatic ductal adenocarcinoma, stage iii breast cancer ajcc v7, stage iii lung non-small cell cancer ajcc v7, stage iii lung small cell carcinoma ajcc v7, stage iii pancreatic cancer ajcc v6 and v7, stage iiia breast cancer ajcc v7, stage iiia lung non-small cell cancer ajcc v7, stage iiia lung small cell carcinoma ajcc v7, stage iiib breast cancer ajcc v7, stage iiib lung non-small cell cancer ajcc v7, stage iiib lung small cell carcinoma ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, stage iv lung non-small cell cancer ajcc v7, stage iv lung small cell carcinoma ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, triple-negative breast carcinoma, unresectable lung small cell carcinoma, unresectable pancreatic adenocarcinoma, unresectable pancreatic carcinoma, unresectable triple-negative breast carcinoma
• Phase: II
• Trial ID: NCT02498613
• Protocol ID: 18-714

Trial Description: This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

• Conditions: clear cell renal cell carcinoma (ccrcc), melanoma, non-small cell lung cancer (nsclc)
• Phase: I/II
• Trial ID: NCT02771626
• Protocol ID: 16-379

Trial Description: The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC). The primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

• Conditions: nsclc
• Phase: I/II
• Trial ID: NCT04077099
• Protocol ID: 19-506

Trial Description: This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

• Conditions: non-small cell lung cancer
• Phase: III
• Trial ID: NCT04351555
• Protocol ID: 21-565

Trial Description: Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT03944772
• Protocol ID: 19-368

Trial Description: This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT03915951
• Protocol ID: 19-252

Trial Description: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

• Conditions: recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma ajcc v7
• Phase: II/III
• Trial ID: NCT02154490
• Protocol ID: 14-416

Trial Description: This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT04302025
• Protocol ID: 20-098

Trial Description: DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations

• Conditions: locally advanced or metastatic non-small cell lung cancer
• Phase: III
• Trial ID: NCT05048797
• Protocol ID: 22-575

Trial Description: The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.

• Conditions: her2 amplification, her2 gene mutation, her2 mutant non-small cell lung cancer, her2-positive metastatic breast cancer
• Phase: I
• Trial ID: NCT05650879
• Protocol ID: 23-167

Trial Description: A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

• Conditions: castration resistant prostate cancer (crpc), follicular lymphoma (fl), small cell lung cancer (sclc)
• Phase: I
• Trial ID: NCT03460977
• Protocol ID: 18-159

Trial Description: A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).

• Conditions: advanced solid tumor, alk gene mutation, metastatic solid tumor, non small cell lung cancer, non-small cell lung cancer, nsclc
• Phase: I/II
• Trial ID: NCT04849273
• Protocol ID: 21-288

Trial Description: The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

• Conditions: breast cancer, non small cell lung cancer
• Phase: II
• Trial ID: NCT02779751
• Protocol ID: 16-216

Trial Description: This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

• Conditions: stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer
• Phase: II
• Trial ID: NCT04062708
• Protocol ID: 20-642

Trial Description: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

• Conditions: advanced solid tumors, metastatic breast cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer
• Phase: I/II
• Trial ID: NCT03568656
• Protocol ID: 21-430

Trial Description: The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

• Conditions: non-small cell lung cancer
• Phase: II
• Trial ID: NCT04926831
• Protocol ID: 21-631

Trial Description: This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a period of improvement (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.

• Conditions: metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8
• Phase: I
• Trial ID: NCT02496663
• Protocol ID: 16-726

Trial Description: BDTX-1535-101 is a first-in-human, open-label, Phase 1 dose escalation and multiple expansion cohort study designed to evaluate the safety, tolerability, pharmacokinetics (PK), central nervous system (CNS) activity, and preliminary antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations with or without CNS disease, or glioblastoma multiforme (GBM) expressing EGFR alterations. All patients will self administer BDTX-1535 monotherapy in 21-day cycles. One expansion cohort will include patients with newly diagnosed GBM who will self administer BDTX-1535 in combination with temozolomide in 28-day cycles.

• Conditions: advanced lung carcinoma, advanced non-small cell squamous lung cancer, advanced solid tumor, egfr gene mutation, gbm, glioblastoma, metastatic cancer, metastatic lung cancer, metastatic lung non-small cell carcinoma, new diagnosis tumor, non-small cell lung cancer, nsclc, recurrent glioblastoma
• Phase: I
• Trial ID: NCT05256290
• Protocol ID: 22-295